# R1 Clinical-Safety Review - gangliocytoma (management narrative)

VERDICT: APPROVE

Confidence: 90

Adversarial .verdict.md: NOT PRESENT (checked same path with .verdict.md). Reviewed sidecar on its own merits.

Goldens changed: no (intended: n/a - reference-content narrative, not engine/rule logic).

## 1. SAFETY - PASS
No unsafe, misleading, or harmful directive. Core claims are clinically correct and conservative:
- Gangliocytoma is a benign, slow-growing neuronal tumor (WHO grade 1); surgery is the mainstay and generally curative for the typical cortical lesion - correct and appropriately hedged ("generally curative", not "always").
- "No established, disease-specific role for radiotherapy or systemic therapy" - correct; RT/cytotoxics are not standard for a benign non-infiltrative lesion, and the draft confines them to the rare atypical/unresectable/recurrent case-by-case setting rather than endorsing them.
- Lhermitte-Duclos / dysplastic cerebellar gangliocytoma linked to Cowden syndrome and germline PTEN, with Cowden-associated surveillance (breast, thyroid, endometrial) - correct.
- Epilepsy-surgery framing (video-EEG, eloquent-cortex caution, neuropsych risk) is sound and safe.
No absolute overstep that would harm a clinician who followed it.

## 2. GROUNDING - PASS
This is the draft's strongest point. It does NOT attribute any claim to DeVita. It states up front and in the Sources line that DeVita 12th ed. was searched and contains no gangliocytoma section (only ganglioglioma, a histologically distinct glioneuronal entity), and labels every clinical claim "general oncology standard, not from DeVita's section on this disease." No fabricated or outdated regimen. No mis-sourcing to DeVita - the specific failure mode the task warns against is avoided.

## 3. DOSE-FREE - PASS
No mg, mg/m2, AUC, numbered schedules, or drug names. "Antiepileptic drug management" and "germline PTEN testing" are modality references, not doses. Confirmed dose-free.

## 4. SCOPE - PASS
Decision-support tone throughout: "can be reasonable", "reserved for", "case-by-case basis", "consider". No directive commands. Refer-out guidance is appropriate.

## Advisory (non-blocking, do not gate)
- The self-tagging disclaimer "(general oncology standard, not from DeVita's section on this disease)" is repeated ~11 times and is verbose for a patient/clinician-facing field. Consider a single header note + drop the per-bullet repetition. Content is fine; this is readability only.
- Sources line cites NCCN for "epilepsy-surgery principles" - NCCN CNS guidelines do not really cover epilepsy surgery. Since it is already labelled "general neuro-oncology standard" rather than a hard NCCN citation, this is advisory, not a mis-source block. Tighten to "general neuro-oncology / neurosurgical standard" if regenerating.
- The embedded FLAG requesting manual sourcing against a WHO CNS / neuro-oncology reference is appropriate and should be honored before this is treated as fully cited, but it does not block publication of a correctly-hedged, general-standard narrative.

APPROVE: clinically safe, dose-free, appropriately scoped, and grounded with no claim mis-attributed to DeVita.
